People

Oliver Eng, MD

  • Assistant Professor of Surgery
  • Research and Scholarly Interests: Appendix Cancer, Cancer of the Gastrointestinal Tract, Colon Cancer, Cytoreductive Surgery, Gastric Cancer, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Metastasectomy, Peritoneal Disease, Peritoneal Mesothelioma, Retroperitoneal Neoplasms
  • Websites: Research Network Profile
  • Contact: oeng@surgery.bsd.uchicago.edu

Oliver Eng, MD, is a double board-certified surgeon and surgical oncologist who focuses on the treatment of cancers in the abdomen, and in particular, cancers that have spread to the peritoneum, the membrane that lines the abdominal cavity. He specializes in complex cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) for locally advanced and metastatic cancers which have disseminated in the abdomen. HIPEC entails delivering high-dose heated chemotherapy in the operating room after surgical removal of visible disease, and is effective in different types of cancers.



Dr. Eng treats a variety of abdominal cancers and is skilled at minimally invasive robotic approaches for gastrointestinal and hepatobiliary malignancies, which enables the removal of tumors through small incisions. He also has expertise in the management of sarcomas, neuroendocrine tumors, metastatic cancers to the liver and malignant bowel obstructions.



Dr. Eng has published numerous peer-reviewed manuscripts in journals, including JAMA Surgery and Annals of Surgical Oncology. His research centers on better understanding the molecular and immunologic characteristics of peritoneal tumors, as well as optimizing outcomes and care for cancer patients. His work has been presented nationally and internationally, and he is the principal investigator or co-investigator on multiple clinical trials. He has co-authored many book chapters and serves as a reviewer for a variety of scientific journals.

City of Hope National Medical Center
- Fellowship

Rutgers University - Robert Wood Johnson Medical School
- Residency

Rutgers University - Robert Wood Johnson Medical School
- MD

Brown University
- ScB

Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.
Berger Y, Schuitevoerder D, Vining CC, Alpert L, Fenton E, Hindi E, Liao CY, Shergill A, Catenacci DVT, Polite BN, Eng OS, Turaga KK. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2020 Sep 05.
PMID: 32892267

Apples to Oranges: Ethical Considerations in COVID-19 Surgical Recovery.
Eng OS, Tseng J, Ejaz A, Pawlik TM, Angelos P. Apples to Oranges: Ethical Considerations in COVID-19 Surgical Recovery. Ann Surg. 2020 08; 272(2):e52.
PMID: 32675494

Cancer Surgery During COVID-19: How We Move Forward.
Eng OS, Pawlik TM, Ejaz A. Cancer Surgery During COVID-19: How We Move Forward. Ann Surg. 2020 08; 272(2):e94-e95.
PMID: 32675508

Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement.
Liu JB, Schuitevoerder D, Vining CC, Berger Y, Turaga KK, Eng OS. Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement. Ann Surg Oncol. 2020 Jul 29.
PMID: 32729047

Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative.
Gamboa AC, Lee RM, Turgeon MK, Zaidi MY, Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Mogal H, Patel SH, Lee TC, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Cloyd JM, Maithel SK, Staley CA. Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Jul 21.
PMID: 32696303

Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States.
Schuitevoerder D, Sherman SK, Izquierdo FJ, Eng OS, Turaga KK. Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States. Ann Surg Oncol. 2020 09; 27(9):3097-3102.
PMID: 32632884

HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin.
Morgan R, Parsad S, Turaga KK, Eng OS. HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin. Basic Clin Pharmacol Toxicol. 2020 Jul 05.
PMID: 32623784

Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways.
Eng OS, Blakely AM, Lafaro KJ, Fournier KF, Fackche NT, Johnston FM, Dineen S, Powers B, Hendrix R, Lambert LA, Ronnekleiv-Kelly S, Walle KV, Grotz TE, Leiting JL, Patel SH, Dhar VK, Baumgartner JM, Lowy AM, Clarke CN, Mogal H, Zaidi MY, Staley CA, Kimbrough C, Cloyd JM, Lee B, Raoof M. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol. 2020 Jul 05.
PMID: 32627199

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve.
Vining CC, Izquierdo F, Eng OS, Turaga KK. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve. J Surg Oncol. 2020 Jul; 122(1):85-95.
PMID: 32436240

Cancer Surgery During COVID-19: How We Move Forward.
Eng OS, Pawlik TM, Ejaz A. Cancer Surgery During COVID-19: How We Move Forward. Ann Surg. 2020 May 20.
PMID: 32433289

View All Publications